An update on the management of chronic hepatitis B and C infection

Dost Sarpel; Danielle Carter; Isaac Wasserman; Moriah Oxnard; Douglas T. Dieterich

doi:10.1211/CP.2017.20203306

An update on the management of chronic hepatitis B and C infection

Dost Sarpel
, Danielle Carter
, Isaac Wasserman
, Moriah Oxnard
, Douglas T. Dieterich

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to SVR12 rates of >95% in most patient populations. Even previously difficult-to-treat patient populations (patients with HIV co-infection, chronic kidney disease or decompensated cirrhosis) can achieve high SVR12 rates. This review focuses on novel therapies for chronic HBV infection and the development of DAAs for chronic HCV infection.

Original language	English
Journal	Clinical Pharmacist
Volume	9
Issue number	8
DOIs	https://doi.org/10.1211/CP.2017.20203306
State	Published - Aug 2017
Externally published	Yes

Keywords

CccDNA
Complete cure
Direct-acting antivirals
Hepatitis B
Hepatitis C
NS3/4A inhibitors
NS5A inhibitors
NS5B inhibitors

Access to Document

10.1211/CP.2017.20203306

Cite this

@article{883c2286db5144b29de15acd03dda943,

title = "An update on the management of chronic hepatitis B and C infection",

abstract = "Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to SVR12 rates of >95\% in most patient populations. Even previously difficult-to-treat patient populations (patients with HIV co-infection, chronic kidney disease or decompensated cirrhosis) can achieve high SVR12 rates. This review focuses on novel therapies for chronic HBV infection and the development of DAAs for chronic HCV infection.",

keywords = "CccDNA, Complete cure, Direct-acting antivirals, Hepatitis B, Hepatitis C, NS3/4A inhibitors, NS5A inhibitors, NS5B inhibitors",

author = "Dost Sarpel and Danielle Carter and Isaac Wasserman and Moriah Oxnard and Dieterich, \{Douglas T.\}",

year = "2017",

month = aug,

doi = "10.1211/CP.2017.20203306",

language = "English",

volume = "9",

journal = "Clinical Pharmacist",

issn = "1758-9061",

publisher = "Royal Pharmaceutical Society",

number = "8",

}

TY - JOUR

T1 - An update on the management of chronic hepatitis B and C infection

AU - Sarpel, Dost

AU - Carter, Danielle

AU - Wasserman, Isaac

AU - Oxnard, Moriah

AU - Dieterich, Douglas T.

PY - 2017/8

Y1 - 2017/8

N2 - Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to SVR12 rates of >95% in most patient populations. Even previously difficult-to-treat patient populations (patients with HIV co-infection, chronic kidney disease or decompensated cirrhosis) can achieve high SVR12 rates. This review focuses on novel therapies for chronic HBV infection and the development of DAAs for chronic HCV infection.

AB - Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to SVR12 rates of >95% in most patient populations. Even previously difficult-to-treat patient populations (patients with HIV co-infection, chronic kidney disease or decompensated cirrhosis) can achieve high SVR12 rates. This review focuses on novel therapies for chronic HBV infection and the development of DAAs for chronic HCV infection.

KW - CccDNA

KW - Complete cure

KW - Direct-acting antivirals

KW - Hepatitis B

KW - Hepatitis C

KW - NS3/4A inhibitors

KW - NS5A inhibitors

KW - NS5B inhibitors

UR - https://www.scopus.com/pages/publications/85056434226

U2 - 10.1211/CP.2017.20203306

DO - 10.1211/CP.2017.20203306

M3 - Article

AN - SCOPUS:85056434226

SN - 1758-9061

VL - 9

JO - Clinical Pharmacist

JF - Clinical Pharmacist

IS - 8

ER -

An update on the management of chronic hepatitis B and C infection

Abstract

Keywords

Access to Document

Fingerprint

Cite this